FDA Warns of Potential Chemical Exposure With Certain Hemodialysis Machines
The source of the chemicals is from the silicone tubing used as a part of the hydraulics in the machine and the dialysate lines.
Chronic Kidney Disease
Combining Dapagliflozin and Eplerenone Further Reduces Albuminuria in CKD
Study findings suggest the nephroprotective effects of both drug classes are complementary.
Underuse of Diabetic Kidney Disease Therapies Reported
Study findings highlight an “unmet need” for newer therapies.
Colchicine May Lower Risk of CKD Progression
Colchicine, a plant-derived alkaloid, has a broad range of anti-inflammatory effects that interfere with neutrophil function, according to investigators.
FDA to Review Daprodustat for Anemia of Chronic Kidney Disease
The NDA is supported by data from 5 ASCEND phase 3 clinical trials.
RAASi Dose Reduction, Discontinuation in CKD Common After Hyperkalemia
In a study of patients with CKD and/or heart failure on RAASi therapy, the proportion of patients who received dose reductions or had therapy discontinued after new-onset hyperkalemia increased with hyperkalemia severity.
March 2022: Drug Pipeline Updates
A review of regulatory and drug development status updates.
FDA Says No to Vadadustat Approval Due to Safety Concerns
The NDA submission included data from 36 clinical trials involving over 8000 patients.
Elobixibat Improves Constipation in Chronic Kidney Disease
Improvement also seen in lipid metabolism, with increase in LDL cholesterol and decrease in HDL cholesterol
Positive Efficacy Findings Prompt Early Stop of Empagliflozin CKD Trial
The EMPA-KIDNEY study enrolled more than 6600 patients with CKD attributable to a wide range of underlying causes.
